The global biologics safety testing market is experiencing significant growth as the biopharmaceutical industry continues to expand rapidly across vaccines, monoclonal antibodies, cell therapies, and gene therapies. The market is projected to grow from USD 5.57 billion in 2026 to USD 9.66 billion by 2031, registering a CAGR of 11.6% during the forecast period. The market was valued at USD 4.97 billion in 2025.
Biologics safety testing plays a crucial role in ensuring the safety, quality, and regulatory compliance of biologic products before they reach patients. These testing solutions are designed to detect microbial contamination, endotoxins, mycoplasma, viruses, and process-related impurities during biologics development, manufacturing, and batch release processes.
The market includes a wide range of products and services such as analytical assays, testing kits, reagents, instruments, and specialized laboratory services that support biologic drug development and manufacturing. The increasing complexity of biologics production and stricter regulatory requirements are significantly accelerating demand for advanced safety testing solutions.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Rising Biologics Development Drives Market Expansion
The growing pipeline of biologic drugs is one of the major factors driving the biologics safety testing market. Pharmaceutical and biotechnology companies are increasingly focusing on biologics due to their high specificity, improved therapeutic outcomes, and growing application in chronic disease treatment.
Biologics such as monoclonal antibodies, vaccines, recombinant proteins, blood products, and advanced cell and gene therapies require rigorous safety evaluation throughout the manufacturing process. Regulatory agencies worldwide continue to enforce strict quality standards to ensure biologics remain free from contamination and impurities.
As a result, manufacturers are investing heavily in reliable and high-throughput safety testing technologies to maintain product integrity and accelerate regulatory approvals.
North America Leads the Global Market
North America accounted for the largest share of the biologics safety testing market in 2025, representing 43% of the global market. The region’s dominance is supported by a strong biopharmaceutical industry, advanced healthcare infrastructure, and substantial investments in biotechnology research and development.
The presence of major pharmaceutical companies, contract research organizations, and leading testing service providers further strengthens market growth in the region. Additionally, stringent regulatory frameworks established by health authorities continue to drive the adoption of advanced biologics safety testing solutions.
Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144
Products Segment Holds the Largest Share
By offering, the product segment accounted for the largest share of 41.9% in 2025. This segment includes assays, kits, reagents, and instruments used across biologics testing workflows.
The growing demand for rapid, accurate, and automated testing technologies is increasing adoption of advanced analytical products across biologics manufacturing facilities. Companies are continuously developing innovative testing solutions capable of detecting contamination more efficiently while reducing turnaround times.
Pharmaceutical and biotechnology companies emerged as the largest end users, accounting for 56.0% of the biologics safety testing products market in 2025. The increasing production of biologics and biosimilars globally is expected to further strengthen this segment over the coming years.
Leading Companies Strengthen Competitive Landscape
Several major industry players continue to dominate the global biologics safety testing market through strong product portfolios, advanced service capabilities, and strategic expansion initiatives.
Key market leaders include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., and Charles River Laboratories. These companies maintain strong market positions through continuous innovation, extensive testing service networks, and strategic collaborations within the biopharmaceutical ecosystem.
At the same time, emerging companies and specialized startups are gaining traction in niche areas of biologics safety testing. Companies such as Clean Biologics, PathoQuest, and ARL Bio Pharma, Inc. are strengthening their market presence through expertise in advanced microbial detection, viral safety testing, and next-generation sequencing-based quality control solutions.
Technological Advancements Shape the Future
The biologics safety testing industry is rapidly evolving with the integration of automation, AI-driven analytics, and advanced molecular testing technologies. Next-generation sequencing, rapid microbiological methods, and digital quality management systems are helping manufacturers improve testing efficiency and reduce production risks.
As cell and gene therapies continue to grow in importance, demand for highly specialized testing solutions is expected to rise significantly. Manufacturers are increasingly seeking scalable and regulatory-compliant safety testing platforms capable of supporting complex biologic products.
Future Outlook
The future of the biologics safety testing market remains highly promising as the global biologics pipeline continues to expand. Increasing regulatory scrutiny, growing investments in biologics manufacturing, and rising demand for safer therapies are expected to sustain strong market growth over the next decade.
With continuous innovation in analytical technologies and expanding applications across advanced therapeutics, biologics safety testing is set to become an even more critical component of the global biopharmaceutical industry.
Inquire Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=34624144
